Results 141 to 150 of about 84,212 (322)

The Prevalence Role of Monocyte Chemoattractant Protein-1 in Hashimoto's Thyroiditis via Various Stimuli Mechanisms

, 2021
Israa Burhan Raoof, Raghad Abdulmahdi Mohsin, Zahraa Ahmed Okhti   +2 more
openalex   +1 more source

SARS-CoV-2-related atypical thyroiditis

The Lancet Diabetes and Endocrinology, 2020
I. Muller, Daniele Cannavaro, D. Dazzi, D. Covelli, G. Mantovani, A. Muscatello, E. Ferrante, E. Orsi, V. Resi, V. Longari, Marco Cuzzocrea, A. Bandera, Elisa Lazzaroni, A. Dolci, F. Ceriotti, T. Re, A. Gori, M. Arosio, M. Salvi   +18 more
semanticscholar   +1 more source

Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort

International Journal of Dermatology, EarlyView.
Alonso García‐Núñez, Antonio Alcalá Ramírez Del Puerto, Roberto Daza‐García, María Teresa Monserrat‐García, Mercedes Morillo‐Andújar, Javier Jesús Domínguez‐Cruz, Román Barabash‐Neila   +6 more
wiley   +1 more source

Prognostic Significance of Solid Subtype of Papillary Thyroid Carcinoma: Analysis of 63 Patients

Head &Neck, Volume 48, Issue 1, Page 5-12, January 2026.
ABSTRACT Objective Solid subtype of papillary thyroid carcinoma (SSPTC) is an uncommon subtype of papillary thyroid cancer (PTC) and its prognostic significance is still controversial. The aim of this review is to present the clinicopathological features of SSPTC and compare its clinical behavior with classical PTC (cPTC).
Andre Ywata de Carvalho, Felipe D' Almeida Costa, Jose Guilherme Vartanian, Luiz Paulo Kowalski   +3 more
wiley   +1 more source

Thyrotoxic periodic paralysis complicated by life-threatening acute hypercapnic respiratory failure in a Chinese male with painless thyroiditis

, 2018
Yanying Qian, Zhijuan Dai, Cong Zhu, Yaoxin Zhu, Chaoming Wu   +4 more
openalex   +1 more source

Safety and Efficacy Findings From a Phase Ib/II Study of ASP‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Head &Neck, Volume 48, Issue 1, Page 160-174, January 2026.
ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 ...
David M. Cognetti, Joseph M. Curry, Jennifer Johnson, Michael Kwon, Shirley Y. Su, Francisco Civantos, Coral Olazagasti, Joseph Valentino, Susanne M. Arnold, R. Bryan Bell, Michael K. Gibson, Kyle Mannion, Kathryn M. Van Abel, Katharine A. Price, Haiying Dong, Amy H. Thorne, Toshiaki Suzuki, Ann M. Gillenwater   +17 more
wiley   +1 more source

Protective role of selenium on thyroid morphology in iodine‑induced autoimmune thyroiditis in Wistar rats

, 2020
Ioana Vasiliu, Delia-Gabriela Ciobanu-Apostol, Ioana Armașu, Ovidiu Bredetean, Ionela Lăcrămioara Șerban, Cristina Preda   +5 more
openalex   +2 more sources

Diagnostic value of a dynamic artificial intelligence ultrasonic intelligent auxiliary diagnosis system for benign and malignant thyroid nodules in patients with Hashimoto thyroiditis [PDF]

, 2023
Bing Wang, Zheng Wan, Mingbo Zhang, Fengxia Gong, Linlin Zhang, Yukun Luo, Jing Yao, Chen Li, Wen Tian   +8 more
openalex   +1 more source

SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Ziad Reguiai, Leila Asfour, Delphine Staumont‐Sallé, Ángela Hermosa‐Gelbard, Andrea Sechi, Dalia Wajsbrot, Rahmat Ishowo‐Adejumo, Deborah Woodworth, Alexandre Lejeune   +8 more
wiley   +1 more source

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA‐mutated/homologous recombination‐deficient (HRD) patients, is lacking.
Lingying Wu, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Junying Tang, Guonan Zhang, Min Hao, Desheng Yao, Qinglei Gao, Youzhong Zhang, Ruifang An, Rutie Yin, Li Wang, Bairong Xia, Qi Zhou, Hongying Yang, Jianqing Zhu, Kui Jiang, Zhengzheng Chen, Qiang Wu, Wei Duan, Yi Huang, Hui Zhang, Shuqing Wei, Guiling Li, Yuanguang Meng, Ke Wang, Xinfeng Yang, Xianghua Huang, Lingya Pan, Jinjin Yu, Ge Lou, Yu Zhang, Huaijun Zhou, Xiaoqing Guo, Hong Yang, Xiaodong Cheng, Xiumin Li, Wuliang Wang, Hongqin Zhao, Yunxia Li, Yingjie Yang, An Lin, Wenjun Cheng, Lihong Chen, Xiaoying Xie, Wen Di, Yuanjing Hu, Mo Chen, Hongwu Wen, Liping Cai, Xiaohua Wu, Zhongqiu Lin, Quanren Wang, Xinfeng Yang, Ning Li   +56 more
wiley   +1 more source